Madrigal Pharmaceuticals, Inc., known by its ticker symbol MDGL on the stock exchange, is a biopharmaceutical company that has dedicated its resources and efforts to discover, design, and develop superior therapeutic approaches to treat cardiovascular, metabolic, and liver diseases. The company aims to provide novel solutions that address the need for new treatments for such conditions, which in turn, improve patients' quality of life.
Founded in 2011 and headquartered in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals embodies a technology-savvy approach by utilizing advanced chemical and pharmacological science to create its solutions. These innovative methods have led to breakthroughs such as resmetirom, their lead candidate, currently undergoing Phase 3 clinical trials. Resmetirom is being studied for its potential in the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease that, if left untreated, could lead to severe complications such as cirrhosis, liver cancer, and liver failure.
Madrigal Pharmaceuticals, Inc. also works on the development of other drugs for the treatment of dyslipidemia and atherosclerosis—common health issues that relate to high cholesterol levels and the buildup of fats, cholesterol, and other substances in and on the artery walls.
One of the notable aspects of Madrigal Pharmaceuticals is its emphasis on using cutting-edge technology to accelerate drug discovery and development processes, ultimately bringing solutions to market more expediently. This approach underscores the company's commitment to advancing healthcare and improving patients' quality of life.
Moreover, the company is backed by a team of experienced leadership and scientists who are deeply involved in the process, from initial research to clinical trials. Notably, the team adheres to the highest ethical standards in their pursuit of delivering innovative medicines to patients.
Growing from its foundational stage to a pioneering biopharmaceutical company, Madrigal Pharmaceuticals, Inc. embodies relentless dedication to patient care. Their work towards the development of new medicines designed to improve cardiovascular health, metabolism, and liver diseases is truly commendable and gives hope to millions of patients worldwide suffering from these conditions.
In conclusion, with its focus on unmet medical needs, innovative research approaches, and dedication to improving patient outcomes, Madrigal Pharmaceuticals, Inc. holds a significant place in the realm of biopharmaceutical companies. Its prospective growth and contributions feel very much on the horizon, positioning Madrigal as a company to watch in the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) announced it will report its third-quarter 2026 financial results on November 3, providing an update on the commercial performance of Rezdiffra, its approved treatment for MASH. The company is focused on expanding the drug's approved uses and continuing its clinical development program, including an ongoing Phase 3 trial for patients with compensated MASH cirrhosis. Investors can access a webcast of the management discussion.
Madrigal Pharmaceuticals Inc. has granted 9,642 restricted stock units to 26 new non-executive employees in October 2026, as an inducement for employment. These time-based awards will vest over four years, contingent on continued employment, and were approved under Nasdaq Listing Rule 5635(c)(4). This strategy supports recruitment for the biotechnology company developing and commercializing treatments for MASH, including its lead medication, Rezdiffra.
Madrigal Pharmaceuticals announced it will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, before the U.S. financial markets open. Following the announcement, management will host a live webcast at 8 a.m. Eastern Time to discuss the results. The webcast details will be available in the Investor Relations section of the company's website.
Madrigal Pharmaceuticals Inc. (MDGL) recently disclosed $350,000 in lobbying expenditures for Q3 2026, focusing on drug pricing issues. The article also details significant insider selling activity, with executives selling shares worth millions, and mixed hedge fund activity including large position changes by major institutional investors. Analyst price targets for MDGL are also presented, with a median target of $620.0.
BofA Securities has lowered its price target on Madrigal Pharmaceuticals (MDGL) to $533 from $543, while maintaining a Neutral rating on the stock. Despite this adjustment, Madrigal Pharmaceuticals holds an average rating of "buy" among analysts, with a mean price target of $684.95. The article indicates that access to the full details requires a premium subscription.
Madrigal Pharmaceuticals' recent Phase 3 MAESTRO-NASH secondary analysis indicates that its drug, Rezdiffra, effectively treats MASH across various genetic risk variants, suggesting broad applicability. This finding reinforces the drug's potential for a wide MASH patient population, which could positively impact demand and future trial designs. While supporting the investment narrative, near-term success still hinges on commercial delivery, payer contracting, and ongoing outcome studies, with a primary risk being the company's reliance on a single marketed therapy.
Madrigal Pharmaceuticals' Phase 3 MAESTRO-NASH secondary analysis for Rezdiffra shows consistent efficacy across various MASH genetic risk variants, suggesting broad clinical relevance for its lead therapy. This genetic data supports Rezdiffra's potential for wide patient uptake and may influence future demand, trial design, and precision medicine approaches. While the findings are positive, near-term priorities remain commercial execution, payer contracting, and ongoing outcome studies to confirm long-term benefits beyond histology.